Investor Relations
Corporate Profile
We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Copyright West LLC. Minimum 15 minutes delayed.
October 3, 2019
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight™ Human Liver Disease platform
3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-00...
September 4, 2019
Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference
SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-...
August 12, 2019
Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
-- Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH -- -- Raised $98.4 million in aggr...
July 2, 2019
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta...
June 24, 2019
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO , June 24, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-st...
June 19, 2019
Akero Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO , June 19, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-s...